Search - tctmd.com

Displaying 1 - 20 of 55

Sort: Relevancy | Date

News Conference News TCT 2024

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

Caitlin E. Cox

October 31, 2024

Presentation TCT 2024

Debate Con: Never

Presenter: Dominick Angiolillo

October 30, 2024

Presentation TCT 2024

Debate Pro: Always

Presenter: Marco Valgimigli

October 30, 2024

News Conference News TCT 2024

In STEMI, Giving Heparin Pre-Cath Lab May Boost Reperfusion: HELP-PCI

Yael L. Maxwell

October 29, 2024

News Conference News TCT 2024

New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding

Caitlin E. Cox

October 28, 2024

Presentation TCT 2024

TCT 227: Timing and Indications for Cangrelor Use and Transition Modalities to Oral P2Y12 Inhibitors in Patients Undergoing PCI: Insights From the SMILE Study

Presenter: Angelo Oliva

October 27, 2024

Presentation TCT 2023

TCT 657: Aspirin versus P2Y12 inhibitor as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation (AF).

Presenter: Hyunki LEE

October 25, 2023

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

Presentation TCT 2023

TCT 37: The association of CHADS-P2A2RC risk score with clinical outcomes in patients taking P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy following percutaneous coronary intervention

Presenter: Ji-Yeon Kim

October 25, 2023

Presentation TCT 2023

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Presenter: Michael Savage

October 25, 2023

Presentation TCT 2023

TCT 557: Real World Adherence to High Potency P2Y12 Inhibitor Therapy in Patients Treated for ST Elevation Myocardial Infarction

Presenter: Wadie David

October 24, 2023

Presentation TCT 2023

TCT 44: P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study

Presenter: Seung-Yul Lee

October 24, 2023

Presentation TCT 2022

TCT 12: Early Predictors of Left Main and Three-Vessel Coronary Artery Disease in Patients with Non-ST Elevation Acute Coronary Syndrome and Implications for Upstream P2Y12 Inhibitor Administration

Presenter: Rayan Jo Rachwan

September 18, 2022

Presentation TCT 2022

P2Y12 Inhibitors in ACS: Which Agent in Which Patient and When?

Presenter: Davide Capodanno

September 18, 2022

News Conference News TCT 2021

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

Yael L. Maxwell

November 09, 2021

News Conference News TCT 2020

Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

Caitlin E. Cox

October 15, 2020

News Conference News TCT 2020

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

Shelley Wood

October 14, 2020

News Conference News TCT 2020

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

Todd Neale

October 14, 2020

News Conference News TCT 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

L.A. McKeown

October 14, 2020

Presentation TCT 2020

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Presenter: Jennifer Rymer

October 14, 2020

Advertisement

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

Debate Con: Never

Debate Pro: Always

In STEMI, Giving Heparin Pre-Cath Lab May Boost Reperfusion: HELP-PCI

New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding

TCT 227: Timing and Indications for Cangrelor Use and Transition Modalities to Oral P2Y12 Inhibitors in Patients Undergoing PCI: Insights From the SMILE Study

TCT 657: Aspirin versus P2Y12 inhibitor as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation (AF).

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

TCT 37: The association of CHADS-P2A2RC risk score with clinical outcomes in patients taking P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy following percutaneous coronary intervention

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

TCT 557: Real World Adherence to High Potency P2Y12 Inhibitor Therapy in Patients Treated for ST Elevation Myocardial Infarction

TCT 44: P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study

TCT 12: Early Predictors of Left Main and Three-Vessel Coronary Artery Disease in Patients with Non-ST Elevation Acute Coronary Syndrome and Implications for Upstream P2Y12 Inhibitor Administration

P2Y12 Inhibitors in ACS: Which Agent in Which Patient and When?

Conservative Management, Careful Diagnosis Key for Good SCAD Outcomes

Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content